Cookies?
Library Header Image
LSE Research Online LSE Library Services

HPR31 A targeted literature review to identify the dimensions of sustainable global biosimilars markets

Dayer, V, Ofre-Bonet, JM, McGuire, Alistair, Zhang, Y and Sullivan, S (2024) HPR31 A targeted literature review to identify the dimensions of sustainable global biosimilars markets. Value in Health, 27 (6). S200 - S200. ISSN 1098-3015

Full text not available from this repository.

Identification Number: 10.1016/j.jval.2024.03.1101

Abstract

Objectives Biosimilars are biologic medications that are highly similar to, and have no clinically meaningful differences from, existing approved biologics known as “reference products”. Typically, biosimilars are priced below their reference products, creating an economic incentive for use to reduce expenses. However, a variety of challenges to biosimilar development and uptake have arisen across global markets and threaten their sustainability. The objective of this study was to conduct a targeted literature review of the biosimilars literature to identify key sustainability dimensions of this market to inform future research, stakeholder interactions, and policy initiatives aimed at ensuring the long-term viability of global biosimilars markets. Methods We searched publications in PubMed and EMBASE for the period 1/2013 to 9/2023 to identify literature addressing aspects of biosimilar market sustainability using the terms ‘biosimilars’, ‘market sustainability’, ‘market access’, ‘pricing and reimbursement’, ‘market dynamics’, ‘market trends’, and ‘price erosion’. We also searched conference abstracts in those databases and relevant policy documents and white papers from 2019 onward. Among included publications, we identified the most prevalent biosimilar sustainability themes to define key dimensions of ‘sustainability’. Results Among 788 relevant publications, 108 (13.7%) were included. The most commonly referenced sustainability dimensions were: pricing/cost-savings (n=102 studies), barriers to market entry/access (n=84), manufacturer processes (n=72), physician prescription choice (n=64), biosimilar knowledge and preferences (n=40), and biosimilar procurement processes (n=39). Key elements within each dimension were also summarized. Conclusions This study used a contemporary review of the global biosimilars literature to establish the key dimensions of biosimilar market sustainability that should be considered by stakeholders looking to ensure the long-term viability of the market. Our findings will be used to develop a framework to facilitate research, collaboration, and policy focused on optimizing the cost-saving potential of biosimilar therapies across global markets.

Item Type: Article
Official URL: https://www.valueinhealthjournal.com/
Divisions: Health Policy
Subjects: R Medicine > RA Public aspects of medicine
Date Deposited: 27 Aug 2024 13:39
Last Modified: 14 Sep 2024 10:14
URI: http://eprints.lse.ac.uk/id/eprint/124679

Actions (login required)

View Item View Item